Marché des intermédiaires API en Asie-Pacifique – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des intermédiaires API en Asie-Pacifique

Le marché des intermédiaires API de la région Asie-Pacifique a connu une croissance significative en raison de la forte charge de troubles chroniques et de l'augmentation du vieillissement de la population, qui sont les principaux moteurs de la demande du marché.                      

Français Data Bridge Market Research analyse que le marché des intermédiaires API Asie-Pacifique, qui était de 6 914,12 millions USD en 2022, devrait atteindre 12 034,12 millions USD d'ici 2030 et devrait connaître un TCAC de 7,0 % au cours de la période de prévision de 2023 à 2030. Les « intermédiaires pharmaceutiques vétérinaires » dominent le segment des types de produits du marché des intermédiaires API Asie-Pacifique en raison d'une demande accrue d'API à travers le monde. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse des pipelines, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des intermédiaires API en Asie-Pacifique

Market Definition

Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product, which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity. The final drug dosage form is formulated using the APIs and excipient but the APIs are formulated using the raw material which is known as intermediates. API intermediates are the kind of material that is produced in the process of API. The intermediates are the by-product of the active pharmaceutical ingredients and provide the same therapeutic activity as that of APIs. These intermediates are also used to cure different kinds of chronic diseases such as cancers, respiratory diseases, and infectious diseases among others.

Asia-Pacific API Intermediates Market Dynamics

Drivers

• Growing Pharmaceutical Industry

The Asia-Pacific region has witnessed substantial growth in its pharmaceutical industry. Factors such as an aging population, increasing healthcare expenditures, and rising prevalence of chronic diseases drive the demand for pharmaceuticals, thereby boosting the API intermediates market.

• Rising Generic Drug Manufacturing

The region is a prominent hub for generic drug manufacturing. Generic drugs require a constant supply of API intermediates, as they offer cost-effective alternatives to brand-name medications. The expanding generic drug market is a significant driver of API intermediate’s demand.

• Increasing Contract Manufacturing

The trend of outsourcing drug manufacturing to contract development and manufacturing organizations (CDMOs) has gained momentum in the Asia-Pacific region. Pharmaceutical companies, particularly those engaged in research and development, often choose to partner with CDMOs to streamline their operations and focus on core competencies. CDMOs rely on a stable and reliable supply chain, which includes API intermediates suppliers. Ensuring a consistent flow of quality intermediates is vital for CDMOs to meet their client’s needs efficiently. This demand from CDMOs fuels the growth of API intermediates manufacturers.

Opportunities

• Development and Adoption of Biopharmaceuticals and Biosimilar

The Asia-Pacific region has seen a surge in the development and adoption of biopharmaceuticals and biosimilar. These complex molecules often require specialized API intermediates for their production. This presents an opportunity for manufacturers to cater to the specific needs of biopharmaceutical companies. Biopharmaceuticals include monoclonal antibodies, gene therapies, and cell-based therapies, which are gaining prominence in treating various diseases. Manufacturers can invest in the research and development of API intermediates tailored to biopharmaceutical applications.

• Emerging and Markets Expansion

Expanding into emerging markets within the Asia-Pacific region offers significant growth opportunities for API intermediates manufacturers. Countries in Southeast Asia, for instance, are experiencing increased healthcare spending and greater access to healthcare services. These emerging markets represent untapped potential for API intermediates, as pharmaceutical production and research activities expand to meet the growing healthcare needs of their populations. Establishing a presence in these markets can lead to increased demand for intermediates.

Restraints/Challenges

• Regulatory Challenges in API Production

The pharmaceutical industry is highly regulated to ensure patient safety and product quality. Compliance with various international and national regulations and quality standards is mandatory, making regulatory adherence a complex and expensive process. API intermediates manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and undergo rigorous inspections and audits to maintain compliance. Regulatory changes, such as updates to quality standards or new compliance requirements, can pose challenges for manufacturers. Meeting these requirements often requires significant investments in infrastructure, technology, and human resources.

• Competition from Low-Cost Producers

The Asia-Pacific region is home to countries known for their cost-effective manufacturing capabilities, such as China and India. These countries have a competitive advantage due to lower labor and operational costs. As a result, they can produce API intermediates at a lower price point than manufacturers in other regions. This intense price competition can squeeze profit margins for API intermediates manufacturers operating in higher-cost locations. To remain competitive, manufacturers must focus on factors such as product quality, innovation, and service differentiation.

This Asia-Pacific API Intermediates market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific API Intermediates Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In January 2021, Vertellus has been acquired by the company, Pritzker Private Capital who partners with the middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered as leading company or provider of specialty chemicals in different sectors such as healthcare, food and agriculture, personal care, transportation and coatings, so PPC has made a partnership with the company. This helped the company Vertellus to increase their market growth which will drive revenues of the company.

Asia-Pacific API Intermediates Market Scope

The Asia-Pacific API intermediates market is segmented on the basis of type, product, therapeutic type, customers, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Veterinary Drug Intermediates Pharmaceutical
• Bulk Drug Intermediates

Product

• Bromo Compound
• O-Benzyl Salbutamol
• Hemisulfate
• Oxirane
• Bisoprolol Base
• Chiral PCBHP
• Pheniramine Base
• Chlorpheniramine Base
• Brompheniramine Base
• Mepyramine/Pyrilamine Base
• 6-Amino-1,3-Dimethyl Uracil
• Theofylline
• Acefylline
• Xanthine
• Nitriles
• Others

Therapeutics Type

• Autoimmune Diseases
• Oncology
• Metabolic Diseases
• Ophthalmology
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Respiratory Disorders
• Dermatology
• Urology
• Others

Customers

• Direct Users/Pharma Companies
• Traders/Wholesalers/Distributors
• Associations/Govt. Institutions/Pvt Institutions

End-Users

• API Manufacturer
• Finished Product Manufacturer

Canal de distribution

• Appel d'offres direct
• Ventes au détail
• Autres

Analyse/perspectives régionales du marché des intermédiaires API en Asie-Pacifique

Le marché des intermédiaires API de la région Asie-Pacifique est analysé et des informations et tendances sur la taille du marché sont fournies par type, produit, type thérapeutique, clients, utilisateurs finaux et canal de distribution comme référencé ci-dessus.

Les pays couverts dans le rapport sur le marché des intermédiaires API Asie-Pacifique sont la Chine, le Japon, l'Inde, la Corée du Sud, Singapour, la Malaisie, l'Australie, la Thaïlande, l'Indonésie, les Philippines et le reste de l'Asie-Pacifique (APAC).

La Chine est le leader de la croissance dans la région Asie-Pacifique et le segment des produits pharmaceutiques/intermédiaires pharmaceutiques en vrac domine dans ce pays car la Chine est le plus grand producteur mondial d'ingrédients pharmaceutiques actifs. L'Inde est le pays qui connaît la croissance la plus rapide en raison des initiatives gouvernementales croissantes en faveur de la production d'API.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché des intermédiaires API en Asie-Pacifique

Le paysage concurrentiel du marché des intermédiaires API en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché des intermédiaires API en Asie-Pacifique.

Certains des principaux acteurs opérant sur le marché des intermédiaires API de la région Asie-Pacifique sont :

• Sanofi (France)
• Aarti Industries Limited (Inde)
• Aurobindo Pharma (Inde)
• Divi's Laboratories Limited (Inde)
• HIKAL Ltd. (Inde)
• Sandoz International GmbH (Allemagne)
• BASF SE (Allemagne)
• Cambrex Corporation (États-Unis)
• AlzChem Group AG (Allemagne)
• Vasudha Pharma (Inde)
• Anyang General Chemical Co., Ltd. (Corée du Sud)
• Sarex (Inde)
• Sandoo Pharmaceuticals and Chemicals Co., Ltd. (Chine)
• Atul Ltd. (Inde)
• Aceto (États-Unis)
• Supriya Lifescience Ltd. (Inde)
• Vertellus (États-Unis)
• Dishman Carbogen Amcis Ltd (Suisse/Inde)
• Groupe Ganesh (Inde)
• Levachem Company Limited (Chine)

SKU-60968